

# Michael Robert Savona

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8982747/publications.pdf>

Version: 2024-02-01

127  
papers

6,175  
citations

117453

34  
h-index

79541

73  
g-index

133  
all docs

133  
docs citations

133  
times ranked

6324  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-specific comorbidities as prognostic variables for survival in Myelofibrosis. Blood Advances, 2023, 7, 756-767.	2.5	6
2	Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia. Haematologica, 2022, 107, 825-835.	1.7	20
3	Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase. Nature Chemical Biology, 2022, 18, 360-367.	3.9	20
4	A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 523-534.	0.2	3
5	Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia, 2022, 36, 1432-1435.	3.3	5
6	Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination. Pharmaceutics, 2022, 14, 694.	2.0	7
7	High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. Nature Medicine, 2022, 28, 468-471.	15.2	19
8	Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia. Blood Cancer Discovery, 2022, 3, 316-329.	2.6	20
9	Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).. Journal of Clinical Oncology, 2022, 40, 7058-7058.	0.8	3
10	Using a standard implementation science framework to improve clinical trial enrollment for a community Tennessee oncology center.. Journal of Clinical Oncology, 2022, 40, e18586-e18586.	0.8	0
11	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
12	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	0.6	814
13	Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood, 2022, 140, 2170-2174.	0.6	13
14	BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia. Clinical Cancer Research, 2021, 27, 598-607.	3.2	16
15	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood, 2021, 137, 1792-1803.	0.6	123
16	Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. International Journal of Laboratory Hematology, 2021, 43, 426-432.	0.7	3
17	High-resolution 3D abdominal segmentation with random patch network fusion. Medical Image Analysis, 2021, 69, 101894.	7.0	26
18	Validation and estimation of spleen volume via computer-assisted segmentation on clinically acquired CT scans. Journal of Medical Imaging, 2021, 8, 014004.	0.8	4

#	ARTICLE	IF	CITATIONS
19	A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. <i>Blood Advances</i> , 2021, 5, 2279-2283.	2.5	2
20	Health-related quality of life (HRQoL) in patients (pts) with myelodysplastic syndromes (MDS) in the Connect Myeloid Disease Registry.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7040-7040.	0.8	0
21	The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib. <i>Experimental Hematology</i> , 2021, 97, 57-65.e5.	0.2	4
22	IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS7056-TPS7056.	0.8	2
23	Germline risk of clonal haematopoiesis. <i>Nature Reviews Genetics</i> , 2021, 22, 603-617.	7.7	48
24	Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation. <i>Targeted Oncology</i> , 2021, 16, 663-674.	1.7	2
25	A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. <i>Blood Advances</i> , 2021, 5, 4361-4369.	2.5	9
26	Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study. <i>Blood</i> , 2021, 138, 66-66.	0.6	7
27	Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect Â® Myeloid Disease Registry. <i>Blood</i> , 2021, 138, 3686-3686.	0.6	2
28	A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy. <i>Blood</i> , 2021, 138, 1245-1245.	0.6	0
29	Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study. <i>Blood</i> , 2021, 138, 3682-3682.	0.6	1
30	Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 219-225.	0.2	13
31	The evolving role of next generation sequencing in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2020, 188, 224-239.	1.2	11
32	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2020, 382, 140-151.	13.9	335
33	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	2.2	56
34	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	15.2	372
35	Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. <i>Nature Cancer</i> , 2020, 1, 1176-1187.	5.7	137
36	Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the ConnectÂ®MDS/AML Disease Registry. <i>EJHaem</i> , 2020, 1, 58-68.	0.4	5

#	ARTICLE	IF	CITATIONS
37	Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. <i>Blood Advances</i> , 2020, 4, 5825-5835.	2.5	60
38	Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia. <i>Gene</i> , 2020, 752, 144758.	1.0	17
39	Establishing specific response criteria for MDS/MPN - Getting closer to reality?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101170.	0.7	0
40	<i>SF3B1</i> -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , 2020, 136, 157-170.	0.6	195
41	Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model. <i>Targeted Oncology</i> , 2020, 15, 231-240.	1.7	14
42	Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2020, 10, 536-551.	7.7	252
43	Evidence of vaccinia dissemination despite lack of major reaction following smallpox vaccination. <i>Vaccine</i> , 2020, 38, 1589-1592.	1.7	1
44	Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 586-598.	2.5	40
45	Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 8-9.	0.6	26
46	Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2020, 136, 37-38.	0.6	16
47	Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study. <i>Blood</i> , 2020, 136, 13-15.	0.6	7
48	Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. <i>Blood</i> , 2020, 136, 674-683.	0.6	144
49	Validation and optimization of multi-organ segmentation on clinical imaging archives. , 2020, 11313, .		0
50	Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7554-7554.	0.8	0
51	Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).. <i>Journal of Clinical Oncology</i> , 2020, 38, 7518-7518.	0.8	0
52	Molecular diagnostic testing patterns in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the Connect MDS/AML Registry.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7553-7553.	0.8	0
53	Contrast phase classification with a generative adversarial network. , 2020, 11313, .		4
54	Outlier guided optimization of abdominal segmentation. , 2020, 11313, .		1

#	ARTICLE	IF	CITATIONS
55	Learning from dispersed manual annotations with an optimized data weighting policy. <i>Journal of Medical Imaging</i> , 2020, 7, 1.	0.8	2
56	Reduced Insulin Sensitivity in Patients with Myeloid Malignancies and Clonal Hematopoiesis Mutations. <i>Blood</i> , 2020, 136, 27-28.	0.6	0
57	Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 579-584.e1.	0.2	16
58	Mitochondrial Homeostasis in AML and Gasping for Response in Resistance to BCL2 Blockade. <i>Cancer Discovery</i> , 2019, 9, 831-833.	7.7	13
59	The Role of DNA Methyltransferase Inhibitors in the Modern Therapy of MDS. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S77-S79.	0.2	0
60	A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2019, 25, 4907-4916.	3.2	36
61	Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1785-1789.	0.8	2
62	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. <i>Lancet Haematology</i> , 2019, 6, e317-e327.	2.2	71
63	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949.	1.7	93
64	Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3971-3988.	2.9	44
65	An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. <i>Lancet Haematology</i> , 2019, 6, e194-e203.	2.2	97
66	Acceleration of spleen segmentation with end-to-end deep learning method and automated pipeline. <i>Computers in Biology and Medicine</i> , 2019, 107, 109-117.	3.9	14
67	The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes. <i>Nucleic Acids Research</i> , 2019, 47, 3921-3936.	6.5	30
68	SynSeg-Net: Synthetic Segmentation Without Target Modality Ground Truth. <i>IEEE Transactions on Medical Imaging</i> , 2019, 38, 1016-1025.	5.4	163
69	Increased Ripk1-mediated bone marrow necroptosis leads to myelodysplasia and bone marrow failure in mice. <i>Blood</i> , 2019, 133, 107-120.	0.6	30
70	BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 7309-7322.	1.2	16
71	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. <i>Leukemia</i> , 2019, 33, 1747-1758.	3.3	195
72	Improving splenomegaly segmentation by learning from heterogeneous multi-source labels. , 2019, 10949, .		14

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine. Blood, 2019, 134, 846-846.	0.6	55
74	Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. Blood, 2019, 134, 4238-4238.	0.6	2
75	Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib. Blood, 2019, 134, 667-667.	0.6	18
76	Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response. Blood, 2019, 134, 3846-3846.	0.6	2
77	Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration. Blood, 2019, 134, 2957-2957.	0.6	3
78	Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes. Blood, 2019, 134, 4273-4273.	0.6	2
79	CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q). Blood, 2019, 134, 1281-1281.	0.6	0
80	Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis. Blood, 2019, 134, 2959-2959.	0.6	2
81	Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia. Blood, 2019, 134, 2643-2643.	0.6	0
82	Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy. Blood, 2019, 134, 1442-1442.	0.6	0
83	Umbralisib, a novel PI3K $\delta$ and casein kinase-1 $\mu$ inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncology, The, 2018, 19, 486-496.	5.1	178
84	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clinical Cancer Research, 2018, 24, 2294-2303.	3.2	87
85	Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematology,the, 2018, 5, e63-e72.	2.2	95
86	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood, 2018, 131, 1415-1424.	0.6	160
87	Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. Leukemia Research, 2018, 65, 67-73.	0.4	12
88	Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. Cancer, 2018, 124, 4601-4609.	2.0	8
89	Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant. Therapeutic Advances in Hematology, 2018, 9, 251-259.	1.1	4
90	A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discovery, 2018, 8, 1566-1581.	7.7	250

#	ARTICLE	IF	CITATIONS
91	Extended dosing with CCâ€486 (oral azacitidine) in patients with myeloid malignancies. American Journal of Hematology, 2018, 93, 1199-1206.	2.0	54
92	The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood, 2018, 131, 2661-2669.	0.6	313
93	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood, 2018, 131, 855-863.	0.6	105
94	Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern. Blood, 2018, 132, 788-788.	0.6	4
95	Phase 1 trial of pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs).. Journal of Clinical Oncology, 2018, 36, 7031-7031.	0.8	2
96	The BET Inhibitor INCB054329 Primes AML Cells for Venetoclax-Induced Apoptosis. Blood, 2018, 132, 4074-4074.	0.6	0
97	Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica, 2017, 102, 327-335.	1.7	87
98	A phase 2 study of simtuzumab in patients with primary, postâ€polycythaemia vera or postâ€essential thrombocythaemia myelofibrosis. British Journal of Haematology, 2017, 176, 939-949.	1.2	40
99	A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood, 2017, 129, 3165-3174.	0.6	114
100	Therapy for Chronic Myelomonocytic Leukemia in a New Era. Current Hematologic Malignancy Reports, 2017, 12, 468-477.	1.2	10
101	Guadecitabine (SGI-110) in treatment-naïve patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncology, The, 2017, 18, 1317-1326.	5.1	148
102	The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S37-S42.	0.2	1
103	Discovery and biological characterization of potent myeloid cell leukemiaâ€1 inhibitors. FEBS Letters, 2017, 591, 240-251.	1.3	49
104	A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies. Blood, 2017, 130, 640-640.	0.6	3
105	A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).. Journal of Clinical Oncology, 2017, 35, TPS7071-TPS7071.	0.8	0
106	Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. OncoTargets and Therapy, 2016, 9, 2273.	1.0	5
107	High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. Cell Reports, 2016, 16, 2003-2016.	2.9	69
108	Molecular Testing in Patients with Suspected Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2016, 11, 441-448.	1.2	6



#	ARTICLE	IF	CITATIONS
109	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. <i>BMC Cancer</i> , 2016, 16, 652.	1.1	12
110	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-€PD-1 Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 474-480.	1.6	17
111	ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Switched from Imatinib to Nilotinib. <i>Blood</i> , 2016, 128, 3090-3090.	0.6	8
112	Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECTA® Myelodysplastic Syndromes (MDS) and AML Disease Registry. <i>Blood</i> , 2016, 128, 3548-3548.	0.6	4
113	CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies. <i>Blood</i> , 2016, 128, 905-905.	0.6	8
114	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. <i>Blood</i> , 2015, 125, 1857-1865.	0.6	153
115	Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015, 126, 1683-1683.	0.6	10
116	Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal. <i>Blood</i> , 2015, 126, 4050-4050.	0.6	2
117	Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA). <i>Blood</i> , 2015, 126, 458-458.	0.6	7
118	An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML maintenance trial. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS7097-TPS7097.	0.8	0
119	High Resolution Mapping of Active RNA Polymerases Identifies KIT As a Target of BET Inhibitors in t(8;21) AML. <i>Blood</i> , 2015, 126, 1225-1225.	0.6	0
120	A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis. <i>Blood</i> , 2015, 126, 2810-2810.	0.6	0
121	Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 630-639.	1.0	31
122	Are we altering the natural history of primary myelofibrosis?. <i>Leukemia Research</i> , 2014, 38, 1004-1012.	0.4	26
123	A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia. <i>Blood</i> , 2014, 124, 1047-1047.	0.6	5
124	Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial. <i>Blood</i> , 2014, 124, 2313-2313.	0.6	9
125	Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis. <i>Blood</i> , 2014, 124, 714-714.	0.6	4
126	Molecular monitoring and minimal residual disease in the management of chronic myelogenous leukemia. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 171-178.	0.1	4



#	ARTICLE	IF	CITATIONS
127	CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response. <i>Blood</i> , 2014, 124, 4638-4638.	0.6	0